Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma

Pt must have histo or cyto conf papillary RCC which is metastatic or locally adv & unresectable. Mixed histologies ok if >/= 50% pap. Pt must have measurable dx. Prior resection ok, but 28 days must have lapsed & pt recovered. Pts w/hx of brain mets who are asymptomatic and have not rec'd steroid tx w/in 14 days prior to reg eligible. Anti-seizure meds allowed provided non-enzyme inducing. Pts may have rec'd up to one prior systemic tx for adv or met RCC but 21 days must have lapsed (42 for nitrosoureas or mitomycin C). No prior MET inhibitor or erlotinib. Prior RT ok if measurable dx outside RT port and 21 days lapsed. Must be offered specimen banking. Zubrod 0-2. WBC >/=2000, ANC >/= 1000, PLT >/=75000, bili </= 1.5 ULN, SGOT & SGPT </= 1.5 ULN, creatinine </= 2 x ULN w/in 14 days prior to reg. Na, K & Ca w/in 14 days prior to reg. Prestudy physical exam & med hx w/in 28 days prior to reg. Must not have hx of corneal diseases in 5.13. Not known to be HIV+ and rec'g anti-retroviral tx. Able to take oral meds. No GI disease req'g IV alimentation, prior surgery affecting absorption, active peptic ulcer disease. Not rec'g nor planning to receive other inv agents. Not pregnant or nursing and agreed to use effective contraception method. No prior malignancy.